The role of probiotics in managing premenstrual syndrome: insights into beneficial bacterial strains

Priyadharshini R.; Subhashini R.

doi:10.18203/2319-2003.ijbcp20251070

Authors

Priyadharshini R. Swamy Vivekananda College of Pharmacy, Namakkal, Tamil Nadu, India
Subhashini R. Swamy Vivekananda College of Pharmacy, Namakkal, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20251070

Keywords:

Premenstrual disorders, Gut microbiota, Gut-brain axis, Probiotics, Cytokine production, Immune modulation, Hormone-related disorders

Abstract

Premenstrual disorders (PMDs), encompassing premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), affect a significant number of women globally. Despite various hypothesized causes like hormonal shifts, serotonin imbalances, and lifestyle factors, the precise etiology remains unclear. Recent research emphasizes the crucial role of the gut microbiota in influencing mental and physical health, particularly through the gut-brain axis, which facilitates neuroendocrine communication. The gut microbiome's impact on endocrine, metabolic, and immune systems is significant, linking variations in gut microbiota diversity to conditions such as major depressive disorder (MDD) and metabolic disorders. Probiotics, known for modulating gut microbiota, show promise in managing PMDs and primary dysmenorrhea by influencing microbial diversity, metabolite profiles, and inflammatory pathways. Studies indicate that certain probiotic strains regulate cytokine production, enhance immunological tolerance, and may alleviate symptoms of hormone-related disorders. Traditional treatments for primary dysmenorrhea, including NSAIDs and hormonal therapy, often have adverse effects and limited efficacy, making probiotics a safer and potentially more effective alternative. Further research is essential to fully understand the molecular mechanisms of probiotics. However, current evidence suggests they could significantly improve women's reproductive health, reduce premenstrual symptoms, and offer a novel approach to managing primary dysmenorrhea, thereby enhancing the quality of life for affected women.

Metrics

Metrics Loading ...

References

Yonkers KA, O’Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371(9619):1200-10. DOI: https://doi.org/10.1016/S0140-6736(08)60527-9

Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218(1):68-74. DOI: https://doi.org/10.1016/j.ajog.2017.05.045

Takeda T, Koga S, Yaegashi N. Prevalence of premenstrual syndrome and premenstrual dysphoric dis- order in Japanese high school students. Arch Women’s Ment Health. 2010;13(6):535-7. DOI: https://doi.org/10.1007/s00737-010-0181-3

Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scandinavica. 2001;104(2):110-6. DOI: https://doi.org/10.1034/j.1600-0447.2001.00412.x

Wang C, Xu Y. Mechanisms for Sex Differences in Energy Homeostasis. J Mol Endocrinol. 2019;62(2):R129-43. DOI: https://doi.org/10.1530/JME-18-0165

Tao C, Li Z, Fan Y, Li X, Qian H, Yu H, et al. Independent and combined associations of urinary heavy metals exposure and serum sex hormones among adults in NHANES 2013-2016. Environ Pollut. 2021;281:117097. DOI: https://doi.org/10.1016/j.envpol.2021.117097

Davis SR, Wahlin-Jacobsen S. Testosterone in women-the clinical significance. Lancet Diabetes Endocrinol. 2015;3(12):980-92. DOI: https://doi.org/10.1016/S2213-8587(15)00284-3

Hamilton KJ, Hewitt SC, Arao Y, Korach KS. Estrogen Hormone Biology. Curr Top Dev Biol. 2017;25:109-46. DOI: https://doi.org/10.1016/bs.ctdb.2016.12.005

Eyster KM. The Estrogen Receptors: An Overview from Different Perspectives. Methods Mol Biol. 2016;1366:1-10. DOI: https://doi.org/10.1007/978-1-4939-3127-9_1

Goldštajn M, Toljan K, Grgić F, Jurković I, Baldani DP. Sex Hormone Binding Globulin (SHBG) as a Marker of Clinical Disorders. Coll Antropol. 2016;40(3):211-8.

Noyola-Martínez N, Halhali A, Barrera D. Steroid hormones and pregnancy. Gynecol Endocrinol 2019;35(5):376-84. DOI: https://doi.org/10.1080/09513590.2018.1564742

Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45-53. DOI: https://doi.org/10.1016/j.maturitas.2017.06.025

Backstrom T, Haage D, Lofgren M, Johansson IM, Stromberg J, Nyberg S, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011;191:46-54. DOI: https://doi.org/10.1016/j.neuroscience.2011.03.061

Muller PA, Schneeberger M, Matheis F, Wang P, Kerner Z, Ilanges A, Mucida D. Microbiota modulate sympathetic neurons via a gut–brain circuit. Nature. 2020;583(7816):441-6. DOI: https://doi.org/10.1038/s41586-020-2474-7

Nishida K, Sawada D, Kawai T, Kuwano Y, Fujiwara S, Rokutan K. Para-psychobiotic Lactobacillus gasseri CP2305 ameliorates stress-related symptoms and sleep quality. J Appl Microbiol. 2017;123(6):1561-70. DOI: https://doi.org/10.1111/jam.13594

Yonkers KA, Casper RF. Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder. In K.A. Martin (Ed.), UpToDate. 2019. Available at: https://www.uptodate.com/contents/clinical-manifestat ions-and-diagnosis-of-premenstrual-syndrome-and-premenstrual-dysphoric-disorder. Accessed on 2 February 2025.

Nur Azurah AG, Sanci L, Moore E, Grover S. The quality of life of adolescents with menstrual problems. J Pediatr Adolesc Gynecol. 2013;26(2):102-8. DOI: https://doi.org/10.1016/j.jpag.2012.11.004

Fernández-Martínez E, Onieva-Zafra MD, Parra-Fernández ML. The impact of dysmenorrhea on quality of life among Spanish female university students. Int J Environ Res Public Heal. 2019;16:713. DOI: https://doi.org/10.3390/ijerph16050713

Hashim RT, Alkhalifah SS, Alsalman AA, Demah MA, Munira AA, Raghda SQ, et al. Prevalence of primary dysmenorrhea and its effect on the quality of life amongst female medical students at King Saud University, Riyadh, Saudi Arabia. Saudi Med J. 2020;41(3):283-9. DOI: https://doi.org/10.15537/smj.2020.3.24988

Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015;21(6):762-78. DOI: https://doi.org/10.1093/humupd/dmv039

Itani R, Soubra L, Karout S, Deema R, Lina K, Hani MJK. Primary dysmenorrhea: pathophysiology, diagnosis, and treatment updates. Korean J Fam Med. 2022;43(2):101-8. DOI: https://doi.org/10.4082/kjfm.21.0103

Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006;332:1134-8. DOI: https://doi.org/10.1136/bmj.332.7550.1134

Harel Z. Dysmenorrhea in adolescents and young adults: from pathophysiology to pharmacological treatments and management strategies. Expert Opin Pharmacother. 2008;9(15):2661-72. DOI: https://doi.org/10.1517/14656566.9.15.2661

Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 1995;9(4):307-12. DOI: https://doi.org/10.3109/09513599509160464

Ma H, Hong M, Duan J, Pei L, Xinsheng F, Erxin S, et al. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. PLoS One. 2013;8(2):e55200. DOI: https://doi.org/10.1371/journal.pone.0055200

Dawood MY. Primary dysmenorrhea. Obstet Gynecol. 2006;108(2):428-41. DOI: https://doi.org/10.1097/01.AOG.0000230214.26638.0c

Barcikowska Z, Rajkowska-Labon E, Grzybowska ME, Hansdorfer-Korzon R, Zorena K. Inflammatory markers in dysmenorrhea and therapeutic options. Int J Environ Res Public Health. 2020;17(4):1191. DOI: https://doi.org/10.3390/ijerph17041191